Treating Cocaine Addiction: From Preclinical to Clinical Trial Experience With γ-Vinyl GABA

Synapse

Volumn 50, Issue 3, 2003, Pages 261-265

  Brodie, Jonathan D ^a   Figueroa, Emilia ^b   Dewey, Stephen L ^a,c  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Clin Intg Tratamiento Contra Adic   (Mexico)

^c BROOKHAVEN NATIONAL LABORATORY   (United States)

Author keywords

Clinical trial; Cocaine addiction; Gamma vinyl GABA; GVG; Vigabatrin

Indexed keywords

VIGABATRIN;

ADULT; ARTICLE; CLINICAL TRIAL; COCAINE DEPENDENCE; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG SELF ADMINISTRATION; DRUG TOLERABILITY; FEMALE; GABAERGIC TRANSMISSION; HEADACHE; HUMAN; MALE; NONHUMAN; NUCLEUS ACCUMBENS; PLACE PREFERENCE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SOMNOLENCE; TREATMENT OUTCOME; WITHDRAWAL SYNDROME;

ADULT; COCAINE-RELATED DISORDERS; ENZYME INHIBITORS; FEMALE; GABA AGENTS; HUMANS; MALE; TREATMENT OUTCOME; VIGABATRIN;

EID: 0142139170     PISSN: 08874476     EISSN: None     Source Type: Journal    
DOI: 10.1002/syn.10278     Document Type: Article

References (37)

1. Ashby CR, Rohatgi R, Ngosuwan J, Borda T, Gerasimov MR, Morgan AE, Kushner S, Brodie JD, Dewey SL. 1999. Implication of the GABA(B) receptor in gamma vinyl-GABA's inhibition of cocaine-induced increases in nucleus accumbens dopamine. Synapse 31: 151-153.
2. Bevins RA, Besheer J, Pickett KS. 2001. Nicotine-conditioned locomotor activity in rats: dopaminergic and GABAergic influences on conditioned expression. Pharmacol Biochem Behav 68:135-145.
3. Bruni J, Guberman A, Vachon L, Desforges C. 2000. Vigabatrin as add-on therapy for adult complex partial seizures: a double-blind, placebo-controlled multicentre study. Seizure Eur J Epilepsy 9:224-232.
4. Buckett WR. 1981. The influence of a GABA transaminase inhibitor, gamma-vinyl GABA, on voluntary morphine consumption in the rat. Psychopharmacology 75:214-216.
5. Dewey SL, Smith GS, Logan J, Brodie JD, Yu DW, Ferrieri RA, King PT, Macgregor RR, Martin TP, Wolf AP, Volkow ND, Fowler JS, Meller E. 1992. GABAergic inhibition of endogenous dopamine release measured in vivo with C-11 raclopride and positron emission tomography. J Neurosci 12:3773-3780.
6. Dewey SL, Morgan AE, Ashby CR, Horan B, Kushner SA, Logan J, Volkow ND, Fowler JS, Gardner EL, Brodie JD. 1998. A novel strategy for the treatment of cocaine addiction. Synapse 30:119-129.
7. Dewey SL, Brodie JD, Gerasimov M, Horan B, Gardner EL, Ashby CR. 1999. A pharmacologic strategy for the treatment of nicotine addiction. Synapse 31:76-86.
8. Ding YS, Studenov AR, Zhang Z, Gerasimov M, Schiffer W, Dewey SL, Telang F. 2001. Synthesis and PET studies of C-11 GVG (vigabatrin) to better understand its role in drug addiction. J Nucl Med 42:424.
9. Eke T, Talbot JF, Lawden MC. 1997. Severe persistent visual field constriction associated with vigabatrin. Br Med J 314:180-181.
10. Foroozan R, Buono LM. 2003. Foggy visual field defect. Surv Ophthalmol 48:447-451.
11. Gardner EL, Schiffer WK, Horan BA, Highfield D, Dewey SL, Brodie JD, Ashby CR. 2002. Gamma-vinyl GABA, an irreversible inhibitor of GABA transaminase, alters the acquisition and expression of cocaine-induced sensitization in male rats. Synapse 46:240-250.
12. Gerasimov MR, Dewey SL. 1999. Gamma-vinyl gamma-aminobutyric acid attenuates the synergistic elevations of nucleus accumbens dopamine produced by a cocaine/heroin (speedball) challenge. Eur J Pharmacol 380:1-4.
13. Gerasimov MR, Schiffer WK, Gardner EL, Marsteller DA, Lennon IC, Taylor SJC, Brodie JD, Ashby CR, Dewey SL. 2001. GABAergic blockade of cocaine-associated cue-induced increases in nucleus accumbens dopamine. Eur J Pharmacol 414:205-209.
14. Hardus P, Verduin WM, Engelsman M, Edelbroek PM, Segers JP, Berendschot T, Stilma JS. 2001. Visual field loss associated with vigabatrin: Quantification and relation to dosage. Epilepsia 42:262-267.
15. Jung M, Lippert B, Metcalf B, Bohlen P, Schechter P. 1977. Gammavinyl GABA (4-amino-hex-5-enoic acid), a new selective irreversible inhibitor of GABA-T: effects on brain GABA metabolism in mice. J Neurochem 29:797-802.
16. Kaufman KR, Lepore FE, Keyser BJ. 2001. Visual fields and tiagabine: a quandary. Seizure Eur J Epilepsy 10:525-529.
17. Kushner SA, Dewey SL, Kornetsky C. 1997. Gamma vinyl GABA attenuates cocaine-induced lowering of brain stimulation reward thresholds. Psychopharmacology 133:383-388.
18. Kushner SA, Dewey SL, Kornetsky C. 1999. The irreversible gamma-aminobutyric acid (GABA) transaminase inhibitor gamma-vinyl-GABA blocks cocaine self-administration in rats. J Pharmacol Exp Ther 290:797-802.
19. Manuchehri K, Goodman S, Siviter L, Nightingale S. 2000. A controlled study of vigabatrin and visual abnormalities. Br J Ophthalmol 84:499-505.
20. Mattson RH, Petroff OAC, Rothman D, Behar K. 1995. Vigabatrin-effect on brain GABA levels measured by nuclear- magnetic-resonance spectroscopy. Acta Neurol Scand 92:27-30.
21. Morgan AE, Dewey SL. 1998. Effects of pharmacologic increases in brain GABA levels on cocaine-induced changes in extracellular dopamine. Synapse 28:60-65.
22. Morgan AE, Dewey SL, Alexoff DL, Horan B, Ashby CR, Logan J, Pappas N, Volkow ND, Brodie JD, King P. 1997. Vigabatrin attenuates cocaine-induced changes in brain dopamine concentrations. J Nucl Med 38:33-33.
23. Nicolson A, Leach JP, Chadwick DW, Smith DF. 2002. The legacy of vigabatrin in a regional epilepsy clinic. J Neurol Neurosurg Psychiatry 73:327-329.
24. Nielsen NV, Syversen K. 1986. Possible retinotoxic effect of carbamazepine. Acta Ophthalmol 64:287-290.
25. Nordmann JP, Baulac M, van Egroo C. 1999. Severe visual field constriction associated with progabide and phenobarbital: a role of GABA-mimetic antiepileptic agents? Invest Ophthalmol Vis Sci 40:366-367.
26. Nousiainen I, Mantyjarvi M, Kalviainen R. 2001. No reversion in vigabatrin-associated visual field defects. Neurology 57:1916-1917.
27. Paul M, Dewey SL, Gardner EL, Brodie JD, Ashby CR. 2001a. Gamma-vinyl GABA (GVG) blocks expression of the conditioned place preference response to heroin in rats. Synapse 41:219-220.
28. Paul SR, Krauss GL, Miller NR, Medura MT, Miller TA, Johnson MA. 2001b. Visual function is stable in patients who continue long-term vigabatrin therapy: implications for clinical decision making. Epilepsia 42:525-530.
29. Schiffer WK, Gerasimov MR, Bermel RA, Brodie JD, Dewey SL. 2000. Stereoselective inhibition of dopaminergic activity by gamma vinyl-GABA following a nicotine or cocaine challenge: a PET/microdialysis study. Life Sci 66:PL169-PL173.
30. Schiffer WK, Marsteller D, Dewey SL. 2003. Subchronic low dose gamma vinyl-GABA (vigabatrin) inhibits cocaine-induced increases in nucleus accumbens dopamine. Psychopharmacology 168:339-343.
31. Schmitz B, Schmidt T, Jokiel B, Pfeiffer S, Tiel-Wilck K, Ruther K. 2002. Visual field constriction in epilepsy patients treated with vigabatrin and other antiepileptic drugs: a prospective study. J Neurol 249:469-475.
32. Stromberg M, Mackler S, Volpicelli J, O'Brien C, Dewey S. 2001. The effect of gamma-vinyl-GABA on the consumption of concurrently available oral cocaine and ethanol in the rat. Pharmacol Biochem Behav 68:291-299.
33. Takada K, Yanagita T. 1997. Drug dependence study on vigabatrin in rhesus monkeys and rats. Arzneimittelforschung/Drug Res 47: 1087-1092.
34. Vanhatalo S, Alen R, Riikonen R, Rantala H, Aine MR, Mustonen K. 2001. Reversed visual field constrictions in children after vigabatrin withdrawal-true retinal recovery or improved test performance only? Seizure Eur J Epilepsy 10:508-511.
35. Wegelius K, Halonen T, Korpi ER. 1993. Gamma-vinyl GABA decreases voluntary alcohol-consumption in alcohol-preferring Aa rats. Pharmacol Toxicol 73:150-152.
36. Wohlrab G, Boltshauser E, Schmitt B, Schriever S, Landau K. 1999. Visual field constriction is not limited to children treated with vigabatrin. Neuropediatrics 30:130-132.
37. Xi ZX, Stein EA. 2000. Increased mesolimbic GABA concentration blocks heroin self-administration in the rat. J Pharmacol Exp Ther 294:613-619.